Content area

|
|

Statens investering i kliniske forsøg

Forfatter(e)
Sofie Louise Rygård, Maj-Brit Nørregaard Kjær & Anders Perner Intensiv Terapiklinik, Rigshospitalet Ugeskr Læger 2018;180:V09170645
Reference: 
Ugeskr Læger 2018;180:V09170645
Blad nummer: 
Sidetal: 
2-4
Danish public research investments in clinical trials
Clinical trials are important to ensure that patients and society benefit from healthcare interventions. Among the Danish public research investments in medical sciences the main part of funding is given to preclinical and translational research, and less than ten per cent is given to clinical trials. This imbalance may have negative consequences for patients and society, because public investment in clinical trials is likely to ensure broader availability of tested interventions independent of diseases, patient groups, caregivers and clinical settings.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Jens Enné Sletgaard | 20/09
3 kommentarer
af Alice Kunkel | 17/09
7 kommentarer
af Jørn Rosborg | 17/09
1 Kommentar
af Peter Christian Gøtzsche | 17/09
1 Kommentar
af Jens Ole Mathiesen | 16/09
3 kommentarer
af Annette Randløv | 16/09
2 kommentarer
af Jens Ole Mathiesen | 15/09
4 kommentarer
af Jens Ole Mathiesen | 14/09
4 kommentarer
af Steffen Thirstrup | 11/09
4 kommentarer